Leukine (sargramostim)

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this website has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Home FAQs Safety Information Prescribing Information Site Map

LEUKINE in AML

LEUKINE goes beyond neutrophil recovery to reduce the risk of fatal infections^1,2

*During and within 30 days of study completion²

The Benefits of LEUKINE

LEUKINE, the CSF that is proven to improve key clinical endpoints in multiple settings, provides a broad range of benefits for you and your patients

Learn More

Learn More

LEUKINE® (sargramostim) is a recombinant granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. LEUKINE is also used in multiple stem cell transplantation settings (click here to read the full indications).

Home

FAQs

Safety Information

Prescribing Information

Site Map